Anzeige
Mehr »
Montag, 21.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
309 Leser
Artikel bewerten:
(1)

Amplity Health's Remote Engagement Center Recognized by J.D. Power for the Fourth Consecutive Year

Amplity Health's Remote Engagement Center Is Named J.D. Power Certified for Providing "An Outstanding Customer Service Experience"

LANGHORNE, PA / ACCESSWIRE / March 30, 2023 / Amplity Health's (Amplity) Remote Engagement Center has once again been recognized by J.D. Power for providing "An Outstanding Customer Service Experience" as an Outsourcer for Pharmaceutical Phone Support.

Amplity Health's Remote Engagement Center Is Named J.D. Power Certified

Amplity Health's Remote Engagement Center Is Named J.D. Power Certified
Amplity Health's Remote Engagement Center Is Named J.D. Power Certified for Providing "An Outstanding Customer Service Experience"



Amplity Health, a leading global medical and commercial partner to biopharmaceutical companies, has been providing remote engagement for decades, responding to patients, caregivers, and healthcare providers (HCPs) on behalf of their pharmaceutical clients. Their fourth consecutive J.D. Power recognition is illustrative of their continued dedication to providing a truly outstanding customer service experience.

"I am reminded of the critical role our customer service team plays in the healthcare continuum every time one of Amplity's representatives speaks with a patient on behalf of one of our clients," said Brian O'Donnell, Amplity's Senior General Manager of Commercial Solutions, who is responsible for field and remote engagement strategies and teams for strategic accounts. Some of the feedback* from patients served by the Amplity team includes:

  • "I am so extremely grateful…[they] worked super hard to help us, and it just makes me feel really good…"
  • "[They] were amazing…[they] were very genuine and had a lot of urgency to help…I just think something like that should be recognized."
  • "I've talked with 3 [customer service team members] in the last few days. They were all very caring and thorough…and I want you to know how much that means to me."

Amplity's Remote Engagement Center is designed to provide multiple channels of personalized assistance, including phone, chat, SMS, e-mail, virtual video, and co-browsing for patients and HCPs. This multichannel approach enables prompt access to critical information, including DTC campaign enrollment, case management, adherence and patient support programs, insurance benefits, copay card activation, and reimbursement management.

"COVID brought a radical change in the way that information is requested and disseminated," explained Christina DiBiase, Amplity's Head of Commercial Solutions. "Amplity was at the forefront of that change given our 40+ years of experience in Remote Engagement. Our Remote Engagement solutions allow customers the option to choose how they want to engage at any given time. By having multiple communication channels available, we are able to best serve the needs of our pharmaceutical clients and their customers."

In an effort to share best practices with the industry, Amplity's Remote Engagement experts have produced several freely available pieces of thought leadership:

  • Which Post-Pandemic Model Is Best for Remote Engagement Teams: Work from Call Center or Work from Home? Understanding the Benefits of Each to Optimize Your Remote Teams
  • The Resounding Call for Blended Customer Engagement Models
  • Do Virtual Teams Need to Work Together in a Call Center? Bringing Teams Back to Call Centers vs. Continuing Remote Work Arrangements
  • Remote Engagement During Pre-Launch: Maximizing Sales and Market Share Through Early Planning
  • Amplity's Blended Engagement Model A New Post-COVID Health Care Provider (HCP) Customer Engagement Model for Pharma

*Customer testimonials are sourced internally and are not in affiliation with the J.D. Power Certified Customer Service Program

About Amplity Health
Amplity Health delivers tailored medical and commercial solutions that scale throughout the lifecycle of a drug. Amplity is a global authority in scientific stakeholder engagement, go-to-market strategies, and is built upon their belief in the power of face-to-face interaction that nurtures trust with physicians, patients, and payers, allowing for the exchange of complex ideas.

Amplity's core strengths include their proprietary network of stakeholders, influencers, and decision makers who they engage through customized personal and non-personal channels; a foundation of qualitative insights and actionable data that informs every solution they craft and execute; their deep expertise and focus on oncology and specialty therapies; their 1,000+ colleagues who live their EPIIC values including more than 300 who hold advanced credentials; and their global operations that reach into more than 40 countries across 6 continents.

For more information, visit amplity.com. Connect with Amplity on Twitter and LinkedIn. Amplity Health is a portfolio company of Altamont Capital Partners.

Contact Information
Gwen Coverdale
Press Relations
gwen.coverdale@amplity.com

SOURCE: Amplity Health

.

View source version on accesswire.com:
https://www.accesswire.com/746568/Amplity-Healths-Remote-Engagement-Center-Recognized-by-JD-Power-for-the-Fourth-Consecutive-Year

© 2023 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.